Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.40 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A3 | P47895 | 4/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30343619 | 1.00 | AR (0.43) | ARPDK2MAOAMAOBTRIM24 | |
| SCHEMBL24779891 | 0.96 | MAOA (0.45) | ARPDK2MAOAMAOBTRIM24 | |
| SCHEMBL31013339 | 0.96 | MAOA (0.45) | ARPDK2MAOAMAOBTRIM24 | |
| SCHEMBL14941705 | 0.84 | TRIM24 (0.52) | ARPDK2MAOAMAOBTRIM24 | |
| SCHEMBL24779097 | 0.80 | KDM4E (0.41) | ARTRIM24TRIM33ALDH1A1KDM4E | |
| SCHEMBL27980876 | 0.79 | MAOA (0.46) | ARPDK2MAOAMAOBTRIM24 | |
| SCHEMBL24779892 | 0.78 | CYP2D6 (0.38) | TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL24779245 | 0.76 | MEN1 (0.43) | MAOAMAOBTRIM24TRIM33ALDH1A1 | |
| SCHEMBL24988105 | 0.74 | TRIM24 (0.67) | TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL24989604 | 0.74 | TRIM24 (0.61) | TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240325572-A1 | N-HETEROCYCLYL SUBSTITUTED 2-CYANO-3-(NAPHTHALEN-2-YL)ACRYLAMIDE DERIVATIVES AS FLUOROPHORS FOR DETECTION OF AMYLOID AND AMYLOID-LIKE PROTEINS FOR DIAGNOSIS OF NEURODEGENERATIVE DISORDERS | Amydis, Inc. | 2024-10-03 | — | — | US | disclosed |
| CN-117916225-A | N-heterocyclyl substituted 2-cyano-3- (naphthalen-2-yl) acrylamide derivatives as fluorophores for detection of amyloid and amyloid-like proteins for diagnosis of neurodegenerative disorders | 阿米达斯公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2023288109-A1 | N-HETEROCYCLYL SUBSTITUTED 2-CYANO-3-(NAPHTHALEN-2-YL)ACRYLAMIDE DERIVATIVES AS FLUOROPHORS FOR DETECTION OF AMYLOID AND AMYLOID-LIKE PROTEINS FOR DIAGNOSIS OF NEURODEGENERATIVE DISORDERS | Amydis, Inc. (US) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325572-A1 | N-HETEROCYCLYL SUBSTITUTED 2-CYANO-3-(NAPHTHALEN-2-YL)ACRYLAMIDE DERIVATIVES AS FLUOROPHORS FOR DETECTION OF AMYLOID AND AMYLOID-LIKE PROTEINS FOR DIAGNOSIS OF NEURODEGENERATIVE DISORDERS | TARDBP, CDR2, NLN | AR 4766/4885PDK2 3631/4885MAOA 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.